GlassScriptPhysician profile
Kiuana S Bright
NPI 1437584141
$6,648.17
in general payments reported to CMS, 2019-2025
24 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $1,260 · 2023: $1,506 · 2024: $1,736 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,014 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,013.59 |
| Education | $230.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,173.22 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $928.37 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $748.98 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $542.41 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $498.41 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $310.91 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $266.99 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $237.93 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $173.40 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $143.13 | 2024-2025 | Qelbree |
| Novo Nordisk INC | $120.33 | 2023 | |
| Gilead Sciences, INC. | $100.00 | 2023 | Epclusa |
| Janssen Pharmaceuticals, INC | $99.86 | 2022-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $61.57 | 2025 | Fanapt |
| Indivior INC. | $48.28 | 2024-2025 | Sublocade |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $45.56 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $29.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.52 | 2021 | |
| Endo Pharmaceuticals INC. | $18.24 | 2021 | |
| Corium, LLC | $17.94 | 2023 | Azstarys |
| Tris Pharma INC | $16.96 | 2023 | Dyanavel Xr |
| Qiagen, LLC | $13.90 | 2021 | |
| Noven Therapeutics, LLC | $13.66 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiuana Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.